defactinib,pembrolizumab
merck,verastem
['pembro', 'defactinib', 'pancreatic']
andrea wang-gillam, md, phd, presents the phase i dose escalation and expansion study of defactinib, pembrolizumab, and gemcitabine in patients with advanced treatment-refractory pancreatic cancer poster (#119) at 8:00am in mccormick place, hall a. #asco22 
A National Cancer Institute Comprehensive Cancer Center and member of the National Comprehensive Cancer Network